Matches in Wikidata for { <http://www.wikidata.org/entity/Q84531531> ?p ?o ?g. }
- Q84531531 description "2012 nî lūn-bûn" @default.
- Q84531531 description "2012年の論文" @default.
- Q84531531 description "2012年学术文章" @default.
- Q84531531 description "2012年学术文章" @default.
- Q84531531 description "2012年学术文章" @default.
- Q84531531 description "2012年学术文章" @default.
- Q84531531 description "2012年学术文章" @default.
- Q84531531 description "2012年学术文章" @default.
- Q84531531 description "2012年學術文章" @default.
- Q84531531 description "2012年學術文章" @default.
- Q84531531 description "2012年學術文章" @default.
- Q84531531 description "2012年學術文章" @default.
- Q84531531 description "2012年學術文章" @default.
- Q84531531 description "2012년 논문" @default.
- Q84531531 description "article científic" @default.
- Q84531531 description "article scientific" @default.
- Q84531531 description "article scientifique" @default.
- Q84531531 description "articol științific" @default.
- Q84531531 description "articolo scientifico" @default.
- Q84531531 description "artigo científico" @default.
- Q84531531 description "artigo científico" @default.
- Q84531531 description "artigo científico" @default.
- Q84531531 description "artikel ilmiah" @default.
- Q84531531 description "artikull shkencor" @default.
- Q84531531 description "artikulong pang-agham" @default.
- Q84531531 description "artykuł naukowy" @default.
- Q84531531 description "artículo científico publicado en 2012" @default.
- Q84531531 description "artículu científicu" @default.
- Q84531531 description "bilimsel makale" @default.
- Q84531531 description "bài báo khoa học" @default.
- Q84531531 description "naučni članak" @default.
- Q84531531 description "scienca artikolo" @default.
- Q84531531 description "scientific article published on 05 July 2012" @default.
- Q84531531 description "scientific article published on 5 July 2012" @default.
- Q84531531 description "scientific article published on 5 July 2012" @default.
- Q84531531 description "teaduslik artikkel" @default.
- Q84531531 description "tieteellinen artikkeli" @default.
- Q84531531 description "tudományos cikk" @default.
- Q84531531 description "vedecký článok" @default.
- Q84531531 description "vetenskaplig artikel" @default.
- Q84531531 description "videnskabelig artikel udgivet 5. juli 2012" @default.
- Q84531531 description "vitenskapelig artikkel" @default.
- Q84531531 description "vitskapeleg artikkel" @default.
- Q84531531 description "vědecký článek" @default.
- Q84531531 description "wetenschappelijk artikel" @default.
- Q84531531 description "wissenschaftlicher Artikel" @default.
- Q84531531 description "επιστημονικό άρθρο" @default.
- Q84531531 description "мақолаи илмӣ" @default.
- Q84531531 description "наукова стаття, опублікована в липні 2012" @default.
- Q84531531 description "научна статия" @default.
- Q84531531 description "научная статья" @default.
- Q84531531 description "научни чланак" @default.
- Q84531531 description "научни чланак" @default.
- Q84531531 description "מאמר מדעי" @default.
- Q84531531 description "مقالة علمية نشرت في 5 يوليو 2012" @default.
- Q84531531 description "৫ জুলাই ২০১২-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ" @default.
- Q84531531 description "บทความทางวิทยาศาสตร์" @default.
- Q84531531 description "სამეცნიერო სტატია" @default.
- Q84531531 name "A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patient" @default.
- Q84531531 name "A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patient" @default.
- Q84531531 type Item @default.
- Q84531531 label "A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patient" @default.
- Q84531531 label "A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patient" @default.
- Q84531531 prefLabel "A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patient" @default.
- Q84531531 prefLabel "A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patient" @default.
- Q84531531 P1433 Q84531531-3184537C-72B0-4721-9C65-8F2A4FCE97BB @default.
- Q84531531 P1476 Q84531531-BEC862F2-55A7-46CB-927D-4051F8320B0E @default.
- Q84531531 P2093 Q84531531-2197BFBE-720E-414F-90FE-932379542E70 @default.
- Q84531531 P2093 Q84531531-2695271D-7B39-4B3C-A67C-7C6875CD6DF3 @default.
- Q84531531 P2093 Q84531531-370BB186-A197-4159-A6C7-A4A1BA4038EF @default.
- Q84531531 P2093 Q84531531-3EC8D422-82B6-4A20-9EA5-FE476FD3097E @default.
- Q84531531 P2093 Q84531531-539F579A-DD27-416D-9212-46E1914AB63B @default.
- Q84531531 P2093 Q84531531-53C7552A-0080-43FA-AFD2-39D9EC1FCE89 @default.
- Q84531531 P2093 Q84531531-BE8D2304-5987-4269-8603-B38487DEC191 @default.
- Q84531531 P2093 Q84531531-C92305B6-4B82-412C-BB0D-D7BDA8B971EB @default.
- Q84531531 P2093 Q84531531-E2808CF7-8445-488D-8338-2E0654E0993D @default.
- Q84531531 P2093 Q84531531-E707ACA2-35D5-404E-B14B-534064711248 @default.
- Q84531531 P2093 Q84531531-EA7DA107-816E-4314-9958-B7D365307CCC @default.
- Q84531531 P304 Q84531531-3182D599-776F-4E93-AF5B-08636B90104A @default.
- Q84531531 P31 Q84531531-73FEA86A-834B-4277-911E-857E9F325FA0 @default.
- Q84531531 P356 Q84531531-DC27C888-95B5-4CB6-BE90-459526309658 @default.
- Q84531531 P433 Q84531531-6BF4EA9E-C083-4FB4-A7AB-6D7A32E5874B @default.
- Q84531531 P478 Q84531531-8507D8C8-C20D-4DD1-B6B7-4A32B914FC3E @default.
- Q84531531 P50 Q84531531-76A42047-4690-427B-B887-29EE5BD03B40 @default.
- Q84531531 P50 Q84531531-7951083B-02BA-4A84-B318-931C4E49B750 @default.
- Q84531531 P50 Q84531531-ADC68C14-8BA9-4052-AA9B-591D57FE579A @default.
- Q84531531 P50 Q84531531-D3BCC8C0-6BBB-4CAC-B4A1-789BC535473D @default.
- Q84531531 P577 Q84531531-A68CE7EF-1BC9-4692-B361-CE8CDC810903 @default.
- Q84531531 P698 Q84531531-75633A46-DCCF-4F5A-8728-09E4AE271180 @default.
- Q84531531 P921 Q84531531-B64B626A-1048-4701-A64F-325FF4EFE41D @default.
- Q84531531 P356 MDS202 @default.
- Q84531531 P698 22767588 @default.
- Q84531531 P1433 Q326122 @default.
- Q84531531 P1476 "A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma" @default.
- Q84531531 P2093 "C Recher" @default.
- Q84531531 P2093 "E Deconinck" @default.
- Q84531531 P2093 "F Lazreg" @default.
- Q84531531 P2093 "F Morschhauser" @default.
- Q84531531 P2093 "G Delsol" @default.
- Q84531531 P2093 "J F Rossi" @default.